Furthermore, as ET-1 levels rise when kidney function declines and endothelin-antagonism may also be reno-protective [29], careful patient selection and/or combination with a diuretic may reveal a subgroup of early HFpEF patients with CKD in which endothelin-antagonism is protective against progression of PVD. Here, EDN1 is linked to chronic kidney disease.